Class IV-G and IV-S lupus nephritis in Chinese patients: A large cohort study from a single center

Lupus

Volumn 18, Issue 12, 2009, Pages 1073-1081

  Yu, F ^a   Tan, Y ^a   Wu, L H ^a   Zhu, S N ^a   Liu, G ^a   Zhao, Ming Hui ^a  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

Author keywords

Class IV G; Class IV S; Lupus nephritis

Indexed keywords

AZATHIOPRINE; CARDIOLIPIN ANTIBODY; COMPLEMENT COMPONENT C1Q ANTIBODY; COMPLEMENT COMPONENT C3; CREATININE; CYCLOPHOSPHAMIDE; HEMOGLOBIN; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G3; LEFLUNOMIDE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISONE;

ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ARTICLE; CHINESE; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REDUCTION; FEMALE; GLOMERULUS CAPILLARY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFLAMMATION; KIDNEY CORTEX NECROSIS; KIDNEY FAILURE; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEINURIA;

ADULT; ANIMALS; ANTIBODIES, ANTICARDIOLIPIN; ASIAN CONTINENTAL ANCESTRY GROUP; AUTOANTIBODIES; COHORT STUDIES; COMPLEMENT C1Q; FEMALE; HUMANS; KIDNEY GLOMERULUS; LUPUS NEPHRITIS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 70349508928     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203309106795     Document Type: Article

References (35)

1. Appel GB, Radhakrishnan J, DAgati VD. Secondary glomerular disease. In: Brenner, BM, (ed), Brenner & Rector's the kidney. 8th ed. Philadephia: W.B.Saunders; 2008. pp. 1067-1146.
2. Appel GB, Silva FG, Pirani CL. Renal involvement in systemic lupus erythematosus (SLE): A study of 56 patients emphasizing histologic classification. Medicine 1978; 75: 371-410.
3. Churg J, Sobin L. Renal disease: Classification and atlas of glomerular disease. Tokyo: Igaku-Shoin; 1982.
4. Churg J, Bernstein J, Classock RJ. Renal disease: Classification and atlas of glomerular disease. Tokyo: Igaku-Shoin; 1995.
5. Weening JJ, D'Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 2004; 65: 521-530.
6. Najafi CC, Korbet SM, Lewis EJ, et al. Significance of histologic patterns of glomerular injury upon long-term prognosis in severe lupus glomerulonephritis. Kidney Int 2001; 59: 2156-2163.
7. Mittal B, Hurwitz S, Rennke H, Singh AK. New subcategories of class IV lupus nephritis: Are there clinical, histologic, and outcome differences? Am J Kidney Dis 2004; 44: 1050-1059.
8. Yokoyama H, Wada T, Hara A, et al. The outcome and a new ISN/RPS 2003 classification of lupus nephritis in Japanese. Kidney Int 2004; 66: 2382-2388.
9. Hill GS, Delahousse M, Nochy D, Bariéty J. Class IV-S versus class IV-G lupus nephritis: Clinical and morphologic differences suggesting different pathogenesis. Kidney Int 2005; 68: 2288-2297.
10. Kim YG, Kim HW, Cho YM, et al. The difference between lupus nephritis class IV-G and IV-S in Koreans: Focus on the response to cyclophosphamide induction treatment. Rheumatology (Oxford) 2008; 47: 311-314.
11. Hochberg MC. Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.
12. Bombardier C, Gladman DD, Hocherg M. Validity and reliability of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989; 32: 1107-1118.
13. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. The derivation of the SLEDAI. A disease activity index for lupus patients. Arthritis Rheum 1992; 35: 630-640.
14. Austin 3rd HA, Muenz LR, Joyce KM, Antonovych TT, Balow JE. Diffuse proliferative lupus nephritis: Identification of specific pathologic features affecting renal outcome. Kidney Int 1984; 25: 689-695.
15. Austin 3rd HA, Boumpas DT, Vaughan EM, Balow JE. Predicting renal outcomes in severe lupus nephritis: Contributions of clinical and histologic data. Kidney Int 1994; 45: 544-550.
16. Wang J, Hu W, Xie H, et al. Induction therapies for class IV lupus nephritis with non-inflammatory necrotizing vasculopathy: Mycophenolate mofetil or intravenous cyclophosphamide. Lupus 2007; 16: 707-712.
17. Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolatemofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005; 353: 2219-2228.
18. Chan TM, Tse KC, Tang CS, Lai KN, Li FK. Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine. Lupus 2005; 14: 265-272.
19. Wang HY, Cui TG, Hou FF, et al. Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: A prospective multi-center observational study. Lupus 2008; 17: 638-644. 17: 638-644.
20. Xin G, Zhao MH, Wang HY. Detection rate and antigenic specificities of antineutrophil cytoplasmic antibodies in Chinese patients with clinically suspected vasculitis. Clin Diagn Lab Immunol 2004; 11: 559-562.
21. Fang QY, Yu F, Tan Y, et al. Anti-C1q antibodies and IgG subclasses distribution in sera from Chinese patients with lupus nephritis. Nephrol Dial Transplant 2009; 24: 172-178.
22. Schwartz MM, Kawala KS, Corwin HL, Lewis EJ. The prognosis of segmental glomerulonephritis in systemic lupus erythematosus. Kidney Int 1987; 32: 274-279.
23. Korbet SM, Lewis EJ, Schwartz MM, Reichlin M, Evans J, Rohde RD. Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group. Am J Kidney Dis 2000; 35: 904-914.
24. Schwartz MM, Roberts JL, Lewis EJ. Necrotizing glomerulitis of systemic lupus erythematosus. Hum Pathol 1983; 14: 158-167.
25. Sen D, Isenberg DA. Antineutrophil cytoplasmic antibodies in systemic lupus erythematosus. Lupus 2003; 12: 651-658.
26. Marshall S, Dressler R, DAgati V. Membranous lupus nephritis with antineutrophil cytoplasmic antibody-associated segmental necrotizing and crescentic glomerulonephritis. Am J Kidney Dis 1997; 29: 119-124.
27. Masani NN, Imbriano LJ, DAgati VD, Markowitz GS. SLE and rapidly progressive glomerulonephritis. Am J Kidney Dis 2005; 45: 950-955.
28. Zhao MH, Liu N, Zhang YK, Wang HY. Antineutrophil cytoplasmic autoantibodies (ANCA) and their target antigens in Chinese patients with lupus nephritis. Nephrol Dial Transplant 1998; 13: 2821-2824.
29. Trendelenburg M, Margarita LT, Eliaka P, et al. High prevalence of anti-C1q antibodies in biopsy-proven active lupus nephritis. Nephrol Dial Transplant 2006; 21: 3115-3121.
30. Frémeaux-Bacchi V, Noël LH, Schifferli JA. No lupus nephritis in the absence of anti-C1q autoantibodies. Nephrol Dial Transplant 2002; 17: 2041-2043.
31. Trendelenburg M, Marfurt J, Gerber I, Tyndall A, Schifferli JA. Lack of occurrence of severe lupus nephritis among anti-C1q autoantibodynegative patients. Arthritis Rheum 1999; 42: 187-188.
32. Trouw LA, Seelen MA, Duijs JM, Benediktsson H, Van Kooten C, Daha MR. Glomerular deposition of C1q and anti-C1q antibodies in mice following injection of anti-mouse C1q antibodies. Clin Exp Immunol 2003; 132: 32-39.
33. Trouw LA, Seelen MA, Visseren R, et al. Anti-C1q antibodies in murine lupus nephritis. Clin Exp Immunol 2004; 135: 41-48.
34. Trouw LA, Duijs JM, van Kooten C, Daha MR. Immune deposition of C1q and anti-C1q antibodies in the kidney is dependent on the presence of glomerular IgG. Mol Immunol 2003; 40: 595-602.
35. Trouw LA, Groeneveld TW, Seelen MA, et al. Anti - C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes. J Clin Invest 2004; 114: 679-688.